vaccine, meningococcal


sanofi pasteur


Zuellig Pharma
Concise Prescribing Info
Meningococcal (groups A, C, Y & W-135) polysaccharide diphtheria toxoid conjugate vaccine
Active immunization of individuals 9 mth-55 yr for prevention of invasive meningococcal disease caused by N meningitidis serogroups A, C, Y & W-135.
Dosage/Direction for Use
0.5 mL IM inj as single dose. Primary vaccination Individual 2-55 yr Given as single dose. Childn 9-23 mth 2-dose series at least 3 mth apart. Booster vaccination Individual 15-55 yr at continued risk for meningococcal disease Single booster dose, at least 4 yr have elapsed since prior dose.
Hypersensitivity to the vaccine or after previous inj. Postpone vaccination in case of moderate or severe febrile or acute disease.
Special Precautions
Hypersensitivity. Not to be inj IV, SC or intradermally. Guillain-Barre syndrome; thrombocytopenia or bleeding disorders. Immunocompromised patients including those receiving immunosuppressant therapy. Syncope. Complement deficiency. Pregnancy & lactation. Not to be used in infants <9 mth. Elderly >55 yr.
Adverse Reactions
Inj site pain, tenderness, irritability; diarrhea, drowsiness, anorexia; headache, fatigue.
Drug Interactions
Reduced immune response w/ immunosuppressive therapies eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Menactra vaccine 0.5 mL/dose
1's;5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in